Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Imaging the Dopamine Systems in Bulimia Nervosa

This study has been completed.
National Institute of Mental Health (NIMH)
Information provided by (Responsible Party):
New York State Psychiatric Institute Identifier:
First received: December 14, 2011
Last updated: August 14, 2014
Last verified: November 2011
This study will use positron emission tomography imaging to investigate the dopamine systems in people with bulimia nervosa.

Eating Disorders

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Cross-Sectional
Official Title: Imaging the Dopamine Systems in Bulimia Nervosa

Resource links provided by NLM:

Further study details as provided by New York State Psychiatric Institute:

Primary Outcome Measures:
  • D2 receptor density [ Time Frame: Measured at baseline ]
  • DA release in the striatum [ Time Frame: Measures after Mythlyphenidate challenge ]

Enrollment: 33
Study Start Date: January 2008
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Participants with Bulimia Nervosa
Participants who are healthy controls


Ages Eligible for Study:   18 Years to 45 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
The study population will include people with bulimia nervosa seeking inpatient or outpatient treatment and people who will act as healthy control participants

Inclusion Criteria:

Participants with BN:

  • Meets DSM-IV criteria for BN
  • Sufficiently medically and psychiatrically stable to participate in research

Health Control Participants:

  • No current or past psychiatric illness
  • Between 80% and 120% of ideal body weight

Exclusion Criteria:

All participants:

  • Current use of psychotropic medication such as anti psychotics or antidepressants
  • Pregnant or breastfeeding
  • history of substance abuse
  • Significant medical illness
  • High blood pressure (resting systolic blood pressure greater than 150mmHg and diastolic blood pressure greater that 90 mmHg)
  • Current or lifetime history of schizophrenia, bipolar disorder, or other psychotic disorder as defined by DSM-IV
  • Metal implants or paramagnetic objects contained within the body that may interfere with the MRI scan, as determined in consultation with a neuroradiologist and according to specified reference book guidelines
  • Exposed to radiation in the workplace or has had a nuclear medicine procedure during the 1 year before study entry
  • Previous adverse reaction to psycho stimulants
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01493362

United States, New York
New York State Psychiatric Institute
New York, New York, United States, 10032
Sponsors and Collaborators
New York State Psychiatric Institute
National Institute of Mental Health (NIMH)
  More Information

Responsible Party: New York State Psychiatric Institute Identifier: NCT01493362     History of Changes
Other Study ID Numbers: #5175
R01MH079397 ( US NIH Grant/Contract Award Number )
Study First Received: December 14, 2011
Last Updated: August 14, 2014

Keywords provided by New York State Psychiatric Institute:
Bulimia Nervosa
PET Imaging

Additional relevant MeSH terms:
Feeding and Eating Disorders
Bulimia Nervosa
Mental Disorders
Signs and Symptoms, Digestive
Signs and Symptoms
Dopamine Agents
Cardiotonic Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Protective Agents processed this record on May 22, 2017